news
Pfizer COVID-19 vaccine set to generate sales of $30 billion
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
List view / Grid view
mRNA-1273
Filter the results
news
UK’s MHRA approves Moderna’s COVID-19 vaccine
The MHRA has given the green light to the Moderna COVID-19 vaccine for use in the UK, making it the third to be approved in the country.
news
Moderna’s COVID-19 vaccine is 94 percent effective, according to trial results
Phase III trial data suggests the mRNA-1273 vaccine is safe and highly effective at preventing COVID-19 in adults.
news
EC orders additional 80 million doses of Moderna’s COVID-19 vaccine
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.
news
First adolescent patients dosed in Phase II/III study of Moderna’s COVID-19 vaccine
The first participants ages 12 to less than 18 have been dosed in the study of mRNA-1273, Moderna's vaccine candidate against COVID-19.
news
Moderna applies for regulatory authorisation for COVID-19 vaccine
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
news
EU secures 80 million doses of Moderna COVID-19 vaccine
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
news
EMA initiates rolling review of Moderna’s COVID-19 vaccine
The rolling review will shorten the approval timeframe by evaluating data on the safety, efficacy and quality of the mRNA-1273 vaccine as it becomes available.
news
Moderna’s COVID-19 vaccine is 94.5 percent effective, according to interim analysis
The analysis reveals that mRNA-1273 was generally well tolerated and prevented COVID-19 with an efficacy of 94.5 percent in a Phase III study.
news
Takeda to supply Japan with Moderna’s COVID-19 vaccine
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
news
COVID-19 vaccine candidate well-tolerated in older adults
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.
news
Moderna to supply US with initial 100 million doses of COVID-19 vaccine
Moderna will supply the US with at least 100 million doses of mRNA-1273, its COVID-19 vaccine candidate currently in Phase III clinical trials.
news
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
news
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
news
Moderna and Catalent to collaborate on COVID-19 vaccine manufacture
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.